An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers

NCT06169579 · clinicaltrials.gov ↗

PHASE1

Phase

ENROLLING_BY_INVITATION

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: ND-003 tablets
DRUG: ND-003 tablets
DRUG: ND-003 tablets
DRUG: ND-003 tablets
DRUG: ND-003 tablets
DRUG: ND-003 tablets
DRUG: ND-003 tablets
DRUG: ND-003 tablets

Sponsor

Shenzhen NewDEL Biotech, Co., Ltd

Collaborators

[object Object]
[object Object]